PART I . Overview We are a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Our scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Our pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted age...
Q2 FY2026 — expected 2026-08-11
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-05 | 2025-12-31 | 0001171843-26-001337 | EDGAR | 81K words |
| 2025-02-27 | 2024-12-31 | 0001171843-25-001106 | EDGAR | — |
| 2024-03-21 | 2023-12-31 | 0001171843-24-001516 | EDGAR | — |
| 2023-03-15 | 2022-12-31 | 0001171843-23-001691 | EDGAR | — |
| 2022-03-18 | 2021-12-31 | 0000950170-22-004156 | EDGAR | — |
| 2021-03-05 | 2020-12-31 | 0001564590-21-011110 | EDGAR | — |
| 2020-06-08 | 2020-03-31 | 0001213900-20-014390 | EDGAR | — |
| 2019-07-01 | 2019-03-31 | 0001213900-19-011850 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-05 | 2025-09-30 | 0001171843-25-007005 | EDGAR | 14K words |
| 2025-08-11 | 2025-06-30 | 0001171843-25-005261 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0001171843-25-002953 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001171843-24-006248 | EDGAR | — |
| 2024-08-12 | 2024-06-30 | 0001171843-24-004670 | EDGAR | — |
| 2024-05-13 | 2024-03-31 | 0001171843-24-002785 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001171843-23-006912 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0001171843-23-004947 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0001171843-23-002868 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001171843-22-007269 | EDGAR | — |
| 2022-08-01 | 2022-06-30 | 0001171843-22-005187 | EDGAR | — |
| 2022-05-09 | 2022-03-31 | 0000950170-22-008244 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-05 | 0001171843-26-001336 | EDGAR | 2K words |
| 2026-01-06 | 0001171843-26-000083 | EDGAR | — |
| 2025-11-05 | 0001171843-25-007004 | EDGAR | — |
| 2025-08-13 | 0001193125-25-179958 | EDGAR | — |
| 2025-08-11 | 0001171843-25-005260 | EDGAR | — |
| 2025-06-12 | 0001171843-25-003868 | EDGAR | — |
| 2025-05-08 | 0001171843-25-002952 | EDGAR | — |
| 2025-04-01 | 0001171843-25-001900 | EDGAR | — |
| 2025-02-27 | 0001171843-25-001105 | EDGAR | — |
| 2025-01-08 | 0001171843-25-000116 | EDGAR | — |
102 total filings indexed. 72 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001738021 |
| Ticker | CMPX |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.compasstherapeutics.com |
| Listed | 2020-11-13 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report